Background: Endogamy in races and ethnic communities contribute to the prevalence of genetic diseases, especially recessive monogenic disorders. The demographic and epidemiological transition also increases the incidence of noncommunicable diseases in underdeveloped and developing countries, including India. Observation: Among all, hemoglobinopathies, cystic fibrosis, Tay-Sachs disease (TSD), etc., prevail in populations of Jewish, Mediterranean, African, and Asian descends. The prevention of births with congenital anomalies of genetic etiology is possible through genetic counseling, carrier screening, and prenatal and/or preimplantation genetic diagnosis. Guidelines have been established by reputed organizations such as American College of Obstetrics and Gynecology (ACOG) and American College of Medical Genetics (ACMG) of different countries with a view to protect the genetic information and misuse of diagnostic samples, selection of the appropriate technologies, clinical application and interpretation of the test results, etc. Conclusion: The integrated approach of community education and counseling in public health assessment can increase awareness about genetic disorders, and also establish an accurate estimate of its prevalence.
IntroductIon
Genetic race or ethnicity refers to different factors including ancestry, social identity, phenotype, genetic makeup, and living practices. Racial groups are susceptible to disease burden mainly due to social inequality and health disparities and, thus, intrinsically affected with high morbidity and mortality. 1, 2 Ambiguous distinction between race and ethnicity could be resolved by the fact that the terms race, genetic population, ethnicity, ancestry, geographic population, etc. are their interchangeable use in a situation of application in different disciplines. Racial health disparities define population-specific differences in the prevalence of diseases, access to health care and outcomes, and life expectancy. Racial health inequity is mainly associated with socioeconomic status, education, gender, and access to medical care, diagnosis, and treatment. 3, 4 The race of understanding the race has started with scientific basis of inheritance and technological challenges for investigation, which is concentrated on deciphering the genetic patterns in some races or ethnic groups. The modern-day admixture of racial groups is creating complexities in self-identification to one ancestry, biological research, and public health policies. 5 Biological ramifications and genetic intersection of race have established a database on the genetic predisposition of human diseases in different racial populations of different geographical provinces. 6 Diseases of racial groups can perpetuate different biological effects that are not predetermined by biology such as lack of basic understanding of life and living, and, thus, adoption of preventive care. Sharing a genetic makeup among individuals from a common ancestry also result in share of certain propensity or resistance to specific diseases. In general, human individuals have 99.9% common genepool, and the difference of 0.1% causes a wide spectrum of variations in both the phenotype and the genotype. 7 In epidemiological risk-calculation of genetic disorders, the race is considered as an adjunct useful tool for the assessment of the variation in disease risks, which considers the genetic ancestry of a population such as Askenazi Jewish (AJ) population. Genetic information is largely determined by inheritance from parents in a 1:1 ratio, which is often confronted by imprinting and incomplete penetration, and thereby causing variation in health-risk. Genetic diseases can be ascribed to a single error in a single gene or more errors in multiple genes wherein environmental and epigenetic factors contribute to significant extents. Globally, over 10,000 human diseases (10/1,000 birth) are monogenic, which could be dominant, recessive, or X-linked (dominant/recessive) for inheritance. Some of the prevalent monogene disorders include thalassemia (most prevalent in populations having Mediterranean ancestry to the point that the disease's name is derived from Greek thalasson, "sea"), sickle cell anemia (most prevalent in populations with sub-Saharan African ancestry but also common among Latin-American, Middle Eastern populations as well as those people of South European regions such as Turkey, Greece, and Italy), hemophilia, cystic fibrosis (the most common life-limiting autosomal recessive disease among people of Northern European heritage), Tay-Sachs disease (TSD) (an autosomal recessive disorder more frequent among AJ than among other Jewish and non-Jewish populations), lactose intolerance (affects over lifetime as many as 25% of Europeans but up to 50-80% of Hispanics, along with AJ, but nearly 100% of Native Americans), fragile X syndrome, Huntington's disease, etc., of which thalassemia stands the most prevalent. 8 Multifactorial polygenic diseases differ in frequency between different populations and are highly complex due to the interaction of both genetic and environmental factors. Races are categorized as low or high risk for some polygene disorders depending on their exposure to certain risk factors. Beyond genetic factors, socioeconomic culture as well as the past and present environmental exposures influence a population's risk for specific diseases.
The present review article has a notion to understand the racial prevalence and the frequency of genetic disorders and their prevention. The genetic abnormalities cannot be treated as of now. Therefore, relying on the principle of "prevention is better than cure," recommended guidelines on prenatal (PND) and preimplantation (PGD) genetic diagnosis have been highlighted with a view to reducing the burden of genetic disorders, which further envisage the necessity of regulatory policies and ethical aspects for PND and PGD screening and diagnosis.
PrevAlence o f GenetIc dIsorders
Interethnic variation is known for a large number of common conditions, including migration, geographic variation, natural selective pressure, and other environmental variables. Information on the population-specific prevalence of genetic disorders is scanty in most of the developing countries including India. Despite multilingual and multicultural habits, Indian population constitute a distinct cluster having a low level of genetic heterogeneity.
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A genome-wide search of South Asian populations has demonstrated that 81 different groups of people have descended from a single "founder event," which is more extreme than that of descendants of the AJ and the Finns. 10 Like other developing countries having demographic and epidemiological transitions, India is also experiencing an increase in obesity, diabetes, and heart disease due to the westernization of culture amidst poverty, predominantly in an urban setting. Also, the amalgamation of people from diverse cultural, social, religious, and tribal backgrounds is causing genetic diversity within racial groups. 11 Association of Indian immunological profile, particularly histocompatibility antigens (HLAs), varies significantly for a number of complex medical diseases and confers varying susceptibility to malaria, tuberculosis, HIV, leprosy, and other infectious diseases. 12, 13 The incidence of heritable genetic disorders in the Indian subcontinents is largely unknown due to lack of defined and concerted estimation program established by the governmental agencies, and/or underestimated because many of the individuals/families remain undiagnosed and unreported. In India, there is no useful official resource to provide the collective national information on the prevalence and the frequency of genetic disorders for the benefit of medical care and/or offering preventive care of the inherited disorders. The reports available are largely from hospital-based small cohort studies and are insufficient to draw a true figure of the total burden of genetic disorders. Consanguineous and interstate (interreligious) marriages could further influence the incidence of genetic illness. 14 Congenital anomalies are the leading cause of infant mortality (20%) across the globe. 15 Yearly, an incidence of 7.9 million birth defects is on the rise even in the post-genomic era. Of this, 3.2 million remain disabled for life. Apart from familial inheritance of single-gene and chromosomal disorders and the result of the multifactorial gene-environment interactions, approximately 50% of all anomalies remain undiagnosed. 16 Genetic etiology is characterized as chromosomal, monogenic, and complex polygenic wherein the genetic makeup is determined at conception following the nuclear event of fertilization, and the major developmental defects are manifested in the prenatal environment.
Chromosomal Disorders
Chromosome abnormalities in the form of aneuploidy and/or structural alterations in autosomes and sex chromosomes could be acquired de novo or inherited in the form of balanced or unbalanced rearrangements. [17] [18] [19] Of all, trisomy 21 is the most common one (1 in 700 births) causing the Down syndrome (DS) followed by trisomies 13 and 18 resulting in Patau and Edward syndromes, respectively (1 in 10,000 births each). Each one is having severe disabilities with specific characteristics and commonness of mental retardation and susceptibility to chronic illness. 20 DS patients can survive till 60 years, but other two die soon after the birth or at the neonatal age. 21, 22 Sex chromosomal aneuploidy commonly includes monosomy X and XXY complements in Turner and Klinefelter syndromes, respectively. 17, 23 Chromosomal aneuploidies occur due to meiotic nondisjunction during gametogenesis, and often influenced by the advanced maternal age. Unbalanced structural alterations could be clinically serious to fatal for a successful liveborn delivery. 17 Moreover, ~95% of conceptuses with aneuploidy or structural alteration do not get embryonic development resulting in the first-trimester miscarriage.
Single-gene Disorders
Single-gene defects are inherited in a dominant or recessive manner from one or both parents. The central dogma of one-gene-oneenzyme hypothesis underlies the majority of single-gene defects such as PAH gene on chromosome 12, which encodes phenylalanine hydroxylase (PAH) enzyme and its malfunctioning causes phenylketonurea (PKU). There are many such metabolic disorders caused by single-gene defects, which are heritable and prevalent among ethnic groups such as sickle cell anemia reported prevalent among Africans, Indians, and Mediterranean descents (Table 1) .
TSD and many other single-gene disorders are prevalent in AJ population, which are grouped as Jewish genetic diseases (JGD) ( Table 2) . 8 TSD is caused by an autosomal recessive mutation in the HEXA gene on chromosome 15 resulting in deficiency in hexosaminidase protein which affects the fatty buildup of the brain and eventually the nervous system. TSD mainly affects young children leading to progressive neural degeneration followed by death during the first few years of life.
Cystic fibrosis is another highly prominent single-gene defect in different racial groups with high frequency and detection rates ( Table 3 ). The culture of endogamy and relatively low admixture increases the inheritance of heterogeneous recessive mutations. Around 1.5 billion population of South Asia has many small endogamous groups, which has presented 81 unique genetic groups with a higher incidence of recessive diseases. 10 The spectrum and the diversity of genetic diseases in this population may actually require a living lab.
Multifactorial Polygenic Disorders
Approximately, 50% of the birth defects remain undiagnosed and are characterized as multifactorial and polygenic. Polygenic defects The contribution of such multiple factors is known to cause abnormalities of the brain and spinal cord including anencephaly (lack most of the brain development), spina bifida (incomplete closure of the spinal cord), etc., which are collectively known as neural tube defects (NTDs). India has an estimate of over 30 million individuals with some kind of neurological disorders. 25 Centers for disease control and prevention (CDC) has presented the US National estimates for selected major birth defects (Table 4) . NTDs are common with varying clinical significance and sometimes associated with trisomy 18. Micronutrient deficiencies such as folate and iodine have been attributed to various malformations including NTDs and mental retardation. Cleft lip and/or palate, autism-like behavioral disorders, etc., are not caused by a single gene but contributed by a set of genes and environmental factors.
PreventIon o f GenetIc dIsorders
The catalog of the recessive mutations shall provide useful guidance on how to prevent or control the transmission of genetic disorders through generations. Such cataloging exercise of JGD has established the "Dor Yeshorim" program that follows premarital screening of AJ and Sephardi Jews with a view to preventing transmission of disease-causing mutations, and that has reduced TSD. 8 However, the burden of genetic diseases can be controlled through integrated approach including community education, population screening, genetic counseling and carrier screening, screening of the newborn, and PND and/or PGD. Carrier screening of hemoglobinopathies and glucose-6-phosphate dehydrogenase (G6PD) deficiency has lowered the incidences. However, the magnitude of the genetic disease and the feasibility of prevention program in a cost-effective manner stand important for controlling the alarming public health issue of birth defects. Nevertheless, awareness about the impact of parents' age, sequel of micronutrient deficiencies, vaccination for rubella and other infections, effects of smoking and alcohol intake, syphilis, other sexually transmitted diseases, etc., on the acquisition of new mutations would combat the development of complex polygenic disorders.
Antenatal screening techniques were described in the 19th century for the management of various genetic disorders and congenital malformations. Evidently, PND has become a norm with exponential evolution from biochemical triple screen to quadruple and then first-trimester double screening in the maternal blood along with ultrasound imaging (Tables 5 and 6 ).
Discovery of cell-free fetal DNA (cff-DNA) in the maternal bloodplasma in 1997 for the screening of trisomies (13, 18, and 21) , which is similar to double screening but with a higher level of precision and sensitivity, has gained importance in prenatal management (Table 7) . However, guidelines have been set for considering cff-DNA by ACOG and others (Table 8) . 28, 29 Altogether, reproductive screening relies on an acceptable test protocol, because the aim is not just early diagnosis for prevention and treatment but also to facilitate reproductive decision making. 28, 29 There is tremendous technological and knowledge-based advancement for screening genes and mutations associated with a growing number of diseases. Analytically, microarray-based comparative genomic hybridization (aCGH) and single-nucleotide polymorphism (SNP) array techniques have validated screening of several disease-causing genes. However, microarray techniques are not capable to detect balanced rearrangements. Sanger and nextgeneration sequencing (NGS) may generate extensive information on the genes and mutations with variants of unknown significance and potential incidental or unsolicited findings and, thus, the clinical use of NGS requires extensive validation. Nevertheless, time-consuming processing and analysis, and high cost debar its use in a clinical setting with the present status. 30, 31 Traditionally, biochemical assessment of hexosaminidase A in serum or leucocytes was followed for the screening of TSD. As the JGDs are caused by a small number of mutations, DNA-based carrier screening has been facilitated by the technological advancement with higher sensitivity and detection rates. Familial dysautonomia was characterized by two mutations in the IKBKAP gene with 99% exclusivity of type 1 mutation in Jewish descendents. Likewise, sequencing of the whole genome or exome may facilitate identification of more disease-causing mutations in the present era. Such development has improved the speed and sensitivity of detection rate at much lower cost. [32] [33] [34] Of 1,700 mutations identified in the CFTR gene, 23 mutations are recommended for carrier screening. 33 Complete analysis of the CFTR gene by DNA sequencing is not appropriate for clinical screening as it may yield unsolicited results that are difficult for interpretation. Therefore, ACMG has strictly recommended appropriate validation of the genetic techniques before their incorporation into routine clinical care for screening or testing. Sequencing of the entire CFTR gene would be meaningful for cases with a family history of the disorder, males with congenital absence of vas deferens (CAVD) or newborns with a positive screening, and when mutation testing with 23 mutation-panel results appears negative. 35 Molecular screening of spinal muscular atrophy (SMA) carrier status involves mainly the deletion of exon 7 of the SMN1 gene in 95% of cases; however, such diagnosis cannot detect heterozygous deletions. Gene dosage analysis has been found to be beneficial to many families with an affected offspring. Quantitative PCR assays have also been implemented for the detection of SMA carriers. Additionally, ~5% of the normal population is reported to carry three copies of SMN1, two copies in one chromosome and an SMN1 deletion on the other resulting in balanced gene dosage. Therefore, the risk of false-negative condition and interpretations of SMA screen shall be managed by experienced genetic professionals and qualified laboratories having validated technologies. 36 ACMG has established standards of care for preconception and prenatal screening of CF and SMA, and several other recessive conditions for reproductive decision-making for ethnic families. 34, 35, 37 Screening of an unprecedented quantity of diseasespecific genetic variants is possible through preconception screening and also in a time-frame suited for PND.
Myths o f Pnd A n d PGd
To know the genetic composition of an unborn child for a decisionmaking, it raises pertinent questions on the benefits and harms of the PND and/or PGD ( Table 8 ). The religious and racial culture might have myths to pose an additional restriction on the approach. The first anxiety of the risk of a miscarriage of invasive sampling (CVS: 1-2% and amniocentesis: 0.5%) is an additional concern of the expecting parents.
To alleviate the fear of inaccuracy of the diagnosis, and selection of the appropriate diagnostic samples and techniques, standard guidelines have been set by the authorized organizations (Table 9) .
conclusIon
The prevalence of diseases has a significant link to diet, environmental, and cultural habits. India having one-sixth of the world population, several thousands of endogamous groups indicate a strong potential for recessive diseases and birth defects. Miscarriages with genetic and congenital anomalies contribute to a considerable amount of perinatal and neonatal mortality, on the one hand, and blood-loss and anemia of the mother, on the other hand. Community genetics services for extending counseling, carrier screening and antenatal and PND/PGD could reduce the prevalence of genetic diseases. Clinical diversities of recessive and dominant mutations in the vast human population pose an urge to changing the system of genetic research. Genetic investigation of natural genetic information in human shall replace the manipulation of knock-out genes in experimental primates. Information on the disease prevalence and frequencies in racial and ethnic cultures has governed major attractions in the postgenomic research. Congenital malformations Cff-DNA screening is not recommended for women with multiple gestations If a fetal structural anomaly is identified on ultrasound examination, diagnostic testing should be offered rather than cell-free DNA screening Patients should be counseled that a negative cell-free DNA test result does not ensure an unaffected pregnancy Cell-free DNA screening does not assess risk of fetal anomalies such as NTDs or ventral wall defects; patients who are undergoing cell-free DNA screening should be offered maternal serum alpha-fetoprotein screening or ultrasound evaluation for risk assessment Patients may decline all screening or diagnostic testing for aneuploidy SMFM, Society for Maternal-Fetal Medicine; ESHG, European Society of Human Genetics; ASHG, American Society of Human Genetics; NSGC, National Society of Genetic Counselors; ISPD, International Society for Prenatal Diagnosis of genetic and nongenetic etiology can be controlled by the public health and governmental agencies. PND and/or PGD shall be recommended as a routine practice with a view to lower the incidence of heritable genetic disorders. Regulations and policies shall be framed to ensure the judicial utilization of technological advances such as embryonic gene editing by CRISPR/Cas9 38 and to follow the concept of personalized medicine and nutrition. 39 
